Come and join us on 6 July and hear 4 AIM CEO’s speak. Brad George, Orosur CEO updates us on Colombia’s Tier-1 gold mine potential, Cliff Gross, CEO at Tekcapital explains how investors benefit from a special dividend. Please register here.

Less Ads, More Data, More Tools Register for FREE

IN BRIEF: EMA starts rolling review of Covid treatment by GSK and Vir

Fri, 7th May 2021 14:08

GlaxoSmithKline PLC - Brentford, Middlesex-based pharmaceutical firm - GSK and Vir Biotechnology Inc say the European Medicines Agency has started a rolling review of test results for their Covid-19 treatment sotrovimab. The review is for use in people 12 years and older. A rolling review means the EMA will evaluate the test data on sotrovimab as it becomes available. A formal marketing authorisation application will be made once there is enough supporting evidence. Sotrovimab has not yet been granted marketing authorisation anywhere in the world, though an Emergency Use Authorization application has been submitted to the US Food & Drug Administration.

Current stock price: 1,350.80 pence

Year-to-date change: up 0.7%

By Tom Waite; thomaslwaite@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

Related Shares

More News

Thursday broker round-up

(Sharecast News) - BP: HSBC downgrades to hold with a target price of 360p.

24 Jun 21 14:13

Deutsche upgrades GSK after strategy day

(Sharecast News) - Deutsche Bank upgraded GlaxoSmithKline to 'hold' and raised its target price on the drugmaker's shares after it set out strategic targets.

24 Jun 21 10:16

BROKER RATINGS: Deutsche raises GSK; HSBC cuts BP to Hold

BROKER RATINGS: Deutsche raises GSK; HSBC cuts BP to Hold

24 Jun 21 09:49

TOP NEWS: AstraZeneca prostate cancer drug Lynparza backed in China

TOP NEWS: AstraZeneca prostate cancer drug Lynparza backed in China

24 Jun 21 08:36

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.